Corcept Therapeutics Incorporated (CORT)
CORT Stock Price Chart
Explore Corcept Therapeutics Incorporated interactive price chart. Choose custom timeframes to analyze CORT price movements and trends.
CORT Company Profile
Discover essential business fundamentals and corporate details for Corcept Therapeutics Incorporated (CORT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
14 Apr 2004
Employees
500.00
Website
https://www.corcept.comCEO
Joseph K. Belanoff
Description
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
CORT Financial Timeline
Browse a chronological timeline of Corcept Therapeutics Incorporated corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Jul 2026
EPS estimate is $0.01, while revenue estimate is $219.13m.
Earnings released on 30 Apr 2026
EPS came in at -$0.30 falling short of the estimated -$0.11 by -172.26%, while revenue for the quarter reached $164.90m , missing expectations by -10.99%.
Earnings released on 24 Feb 2026
EPS came in at $0.20 falling short of the estimated $0.33 by -39.39%, while revenue for the quarter reached $202.13m , missing expectations by -20.72%.
Earnings released on 4 Nov 2025
EPS came in at $0.16 falling short of the estimated $0.18 by -11.11%, while revenue for the quarter reached $207.64m , missing expectations by -18.68%.
Earnings released on 31 Jul 2025
EPS came in at $0.29 surpassing the estimated $0.23 by +26.09%, while revenue for the quarter reached $194.43m , missing expectations by -20.50%.
Earnings released on 5 May 2025
EPS came in at $0.17 matching the estimated $0.17, while revenue for the quarter reached $157.21m , missing expectations by -27.44%.
Earnings released on 26 Feb 2025
EPS came in at $0.26 falling short of the estimated $0.37 by -29.73%, while revenue for the quarter reached $181.89m , missing expectations by -9.11%.
Earnings released on 30 Oct 2024
EPS came in at $0.41 surpassing the estimated $0.28 by +46.43%, while revenue for the quarter reached $182.55m , missing expectations by -7.81%.
Earnings released on 29 Jul 2024
EPS came in at $0.32 surpassing the estimated $0.23 by +39.13%, while revenue for the quarter reached $163.80m , beating expectations by +1.06%.
Earnings released on 1 May 2024
EPS came in at $0.25 surpassing the estimated $0.22 by +13.64%, while revenue for the quarter reached $146.81m , beating expectations by +3.97%.
Earnings released on 15 Feb 2024
EPS came in at $0.28 surpassing the estimated $0.26 by +7.69%, while revenue for the quarter reached $135.41m , beating expectations by +4.72%.
Earnings released on 1 Nov 2023
EPS came in at $0.28 surpassing the estimated $0.22 by +27.27%, while revenue for the quarter reached $123.60m , missing expectations by -3.30%.
Earnings released on 2 Aug 2023
EPS came in at $0.25 surpassing the estimated $0.15 by +66.67%, while revenue for the quarter reached $117.72m , beating expectations by +7.32%.
Earnings released on 3 May 2023
EPS came in at $0.14 falling short of the estimated $0.19 by -26.32%, while revenue for the quarter reached $105.65m , beating expectations by +0.75%.
Earnings released on 28 Feb 2023
EPS came in at $0.14 falling short of the estimated $0.23 by -39.13%, while revenue for the quarter reached $103.06m , missing expectations by -1.93%.
Earnings released on 3 Nov 2022
EPS came in at $0.30 surpassing the estimated $0.23 by +30.43%, while revenue for the quarter reached $101.73m , missing expectations by -5.43%.
Earnings released on 3 Aug 2022
EPS came in at $0.24 matching the estimated $0.24, while revenue for the quarter reached $103.39m , beating expectations by +2.36%.
Earnings released on 5 May 2022
EPS came in at $0.20 falling short of the estimated $0.24 by -16.67%, while revenue for the quarter reached $93.69m , missing expectations by -5.25%.
Earnings released on 15 Feb 2022
EPS came in at $0.26 surpassing the estimated $0.22 by +18.18%, while revenue for the quarter reached $98.82m , missing expectations by -1.74%.
Earnings released on 3 Nov 2021
EPS came in at $0.24 surpassing the estimated $0.20 by +20.00%, while revenue for the quarter reached $96.13m , missing expectations by -1.56%.
Earnings released on 29 Jul 2021
EPS came in at $0.21 surpassing the estimated $0.16 by +31.25%, while revenue for the quarter reached $91.59m , meeting expectations.
CORT Stock Performance
Access detailed CORT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
